Effective Management of Overactive Bladder in Postmenopausal Women

Introduction to Treatment Options

The American Urological Association recommends the combination of solifenacin 5 mg plus mirabegron 50 mg as the most effective medication regimen for overactive bladder in postmenopausal women, offering superior efficacy compared to either medication alone 1, 2

The European Association of Urology suggests beginning with behavioral therapies, including bladder training, as the initial approach for all patients with overactive bladder symptoms 4
Behavioral therapies may be combined with pharmacologic management to optimize symptom control, as recommended by the American Urological Association 4

The International Continence Society recommends proceeding to medication therapy if behavioral therapies alone are insufficient, with combination therapy with solifenacin 5 mg plus mirabegron 50 mg as a preferred option 1, 4
This combination has demonstrated superior efficacy to monotherapy for decreasing incontinence episodes and micturitions, with an additive effect compared to monotherapy 1, 2

The SYNERGY trial demonstrated that combination therapy with solifenacin 5 mg plus mirabegron 50 mg provided greater improvements in urinary incontinence episodes compared to monotherapy, with a significant reduction in incontinence episodes 1
The BESIDE trial showed that combination therapy was superior to solifenacin monotherapy for reducing incontinence episodes, with a higher response rate in the combination therapy group 1
The SYNERGY II trial confirmed that combination therapy was statistically superior to mirabegron and solifenacin monotherapy for decreasing incontinence episodes and micturitions over a 12-month period, with a significant improvement in quality of life 2

The North American Menopause Society suggests that combination therapy with tolterodine and intravaginal estradiol cream may have benefits in menopausal women with OAB, although the evidence is limited 2
The American Geriatrics Society recommends exercising caution when using antimuscarinics in older patients due to potential cognitive effects, with a careful assessment of the risk-benefit ratio 4
The International Continence Society suggests that for women with nocturnal polyuria, combination of desmopressin with antimuscarinic therapy may provide additional benefits, although further studies are needed 2

The American Urological Association recommends assessing for adverse effects, particularly dry mouth, constipation, and blurred vision with antimuscarinics, with regular monitoring and follow-up 3
The European Association of Urology suggests monitoring for potential urinary retention, especially with combination therapy, with a careful assessment of the risk-benefit ratio 2
The International Continence Society recommends evaluating treatment efficacy using symptom questionnaires and/or bladder diaries, with a regular assessment of treatment outcomes 1